New hope for lung cancer patients: experimental drug shows promise in early trial
NCT ID NCT01802632
First seen Apr 30, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tested a new drug called AZD9291 in 603 people with advanced non-small cell lung cancer whose tumors had started growing again after previous targeted therapy. The main goals were to find the safest and most effective dose, measure how the drug moves through the body, and see if it can shrink tumors. The results helped decide the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Nashville, Tennessee, 37232, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Kogarah, 2217, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Pierre-Bénite, 69310, France
-
Research Site
Saint-Herblain, 44805, France
-
Research Site
Villejuif, 94800, France
-
Research Site
Cologne, 50924, Germany
-
Research Site
Essen, 45122, Germany
-
Research Site
Würzburg, 97080, Germany
-
Research Site
Genova, 16100, Italy
-
Research Site
Orbassano, 10043, Italy
-
Research Site
Roma, 00144, Italy
-
Research Site
Chiba, 260-8717, Japan
-
Research Site
Fukuoka, 811-1395, Japan
-
Research Site
Fukuoka, 812-8582, Japan
-
Research Site
Habikino-shi, 583-8588, Japan
-
Research Site
Hirakata-shi, 573-1191, Japan
-
Research Site
Hiroshima, 730-8518, Japan
-
Research Site
Kanazawa, 920-8641, Japan
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Kobe, 650-0047, Japan
-
Research Site
Matsuyama, 790-0007, Japan
-
Research Site
Okayama, 700-8558, Japan
-
Research Site
Shinjuku-ku, 160-0023, Japan
-
Research Site
Sunto-gun, 411-8777, Japan
-
Research Site
Takatsuki-shi, 569-8686, Japan
-
Research Site
Yokohama, 221-0855, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 6351, South Korea
-
Research Site
Madrid, 08035, Spain
-
Research Site
Madrid, 28041, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
Conditions
Explore the condition pages connected to this study.